Table 1.

Clinical trials involving follicular lymphoma patients treated in the first-line and relapsed settings

Reference	Dose regimen	Response rate	PFS
First-line follicular lymphoma
Zucca et al9	15 mg /d with rituximab for 18 wk	OR, 82%; CR, 36%	Median, 5 y
Fowler et al10	20 mg/d days 1-21 (28-d cycle) with rituximab for up to 12 cycles.	OR, 98%; CR, 87%	Median not reached*
			3 y, 79%
Martin et al11	20-25 mg/d days 1-21 (28-d cycle) with rituximab for up to 12 cycles	OR, 95%; CR, 72%	5.y, 72%
Morschhauser et al13	20 mg/d days 1-21 (28-d cycle) with rituximab ×6 cycles followed by 10 mg/d days 1-21 (28-d cycle) for 12 cycles in patients with confirmed or unconfirmed CR.	OR, 61%; CR, 48%	3 y. 77%
Relapsed follicular lymphoma
Witzig et al15	25 mg/d day 1-21 (28-d cycle) for up to 52 wk	OR, 27%; CR, 9%	Median, 4.4 mo
Leonard et al17	15-25 mg/d day 1-21 (28-d cycle), with or without rituximab	Lenalidomide	Lenalidomide:
		OR, 53%; CR, 20%	Median time to progression, 1.1 y
		Lenalidomide+rituximab:	Lenalidomide+rituximab:
		OR, 76%; CR, 39%	Median time to progression, 2 y
Chong et al16	10 mg daily with rituximab	OR, 65%; CR, 35%	Median, 16.5 mo
Andorsky et al19	20 mg/d, day 1-21 (28-d cycle), with rituximab for 12 cycles, followed by 1:1 randomization of patients with ≥ stable disease to maintenance lenalidomide 10 mg, d 1‐21, with rituximab vs rituximab alone	OR, 74%; CR, 46% (for induction phase)	Median, 0.2 mo
Leonard et al18	20 mg/d day 1-21 (28-d cycle) with rituximab for 12 cycles	OR, 78%; CR, 34%	Median, 39.4 mo